全球止血劑市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計止血劑市場將從 2025 年的 37.5 億美元成長到 2034 年的 65.4 億美元，2026 年至 2034 年的複合年成長率為 6.36%。

受全球外科手術和創傷病例數量不斷增加的推動，全球止血劑市場正經歷穩定成長。止血劑在控制手術出血和急診醫學中發揮著至關重要的作用。需要手術介入的慢性疾病盛行率不斷上升以及老年人口的成長，也促使醫療機構對止血劑的需求保持穩定。

關鍵成長要素包括生物來源和合成止血劑的進步，這些進步提高了凝血效率。微創手術的普及和急救醫療基礎設施的改善進一步推動了市場成長。此外，意識提升到在軍事行動和災害應變中快速止血的重要性，也促進了產品的應用。

隨著先進生物材料和複合材料產品的持續研究，未來前景十分光明。新興市場醫療保健投資的增加將創造新的成長機會。創新創傷護理解決方案的整合以及產品安全性的提升，將使全球止血劑市場長期保持成長動能。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球止血劑市場：依產品類型分類

• 市場分析、洞察與預測
• 活性止血劑
• 被動止血劑
• 組合

第5章：全球止血劑市場：依專業/治療領域分類

• 市場分析、洞察與預測
• 心臟病學
• 導管檢查室
• 創傷
• 一般外科
• 婦產科
• 移植
• 腫瘤學
• 神經病學
• 整形外科
• 整形外科
• 牙科
• 其他（泌尿系統手術、肺部手術）

第6章 全球止血劑市場：依通路分類

• 市場分析、洞察與預測
• 大型醫院（500床或以上）
• 中型醫院（250-499床）
• 小規模醫院（床位少於250床）

第7章 全球止血劑市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Baxter International Inc
  • Ethicon Inc
  • Becton
  • Dickinson And Company（BD）
  • B. Braun SE
  • Pfizer Inc
  • Teleflex Incorporated
  • CryoLife Inc
  • Integra LifeSciences Holdings Corporation
  • Advanced Medical Solutions Group Plc
  • GELITA AG

The Hemostatic Agents Market size is expected to reach USD 6.54 Billion in 2034 from USD 3.75 Billion (2025) growing at a CAGR of 6.36% during 2026-2034.

The Global Hemostatic Agents Market is witnessing steady growth driven by increasing surgical procedures and trauma cases worldwide. Hemostatic agents play a critical role in controlling bleeding during surgeries and emergency care. Rising prevalence of chronic diseases requiring surgical intervention and growing geriatric populations are contributing to consistent demand across healthcare facilities.

Major growth drivers include advancements in biologically derived and synthetic hemostatic products that enhance clotting efficiency. Expansion of minimally invasive surgeries and improved emergency care infrastructure are further supporting market expansion. Additionally, increasing awareness about rapid bleeding control in military and disaster response settings is boosting product adoption.

Future prospects appear promising as research into advanced biomaterials and combination products continues. Growing healthcare investments in emerging economies will create new growth opportunities. Integration of innovative wound care solutions and improved product safety profiles will likely sustain long-term expansion in the global hemostatic agents market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• Active Agents
• Passive Agents
• Combination

By Specialty / Therapeutic Area

• Cardiology
• Cath Lab
• Trauma
• General Surgery
• ObGyn
• Transplant
• Oncology
• Neurology
• Orthopedic
• Plastic Surgery
• Dental
• Others (Urological Surgeries, Pulmonary Surgeries)

By Distribution Channel

• Large Hospital (500+ Beds)
• Medium Hospital (250-499 Beds)
• Small Hospitals (Less than 250 Beds)

COMPANIES PROFILED

• Baxter International Inc, Ethicon Inc, Becton, Dickinson and Company BD, B Braun SE, Pfizer Inc, Teleflex Incorporated, CryoLife Inc, Integra LifeSciences Holdings Corporation, Advanced Medical Solutions Group plc, GELITA AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HEMOSTATIC AGENTS MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Active Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Passive Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Combination Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HEMOSTATIC AGENTS MARKET: BY SPECIALTY / THERAPEUTIC AREA 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Specialty / Therapeutic Area
• 5.2. Cardiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cath Lab Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Trauma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. General Surgery Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. ObGyn Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Transplant Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. Orthopedic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.11. Plastic Surgery Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.12. Dental Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.13. Others (Urological Surgeries, Pulmonary Surgeries) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HEMOSTATIC AGENTS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Large Hospital (500+ Beds) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Medium Hospital (250-499 Beds) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Small Hospitals (Less than 250 Beds) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HEMOSTATIC AGENTS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product Type
  • 7.2.2 By Specialty / Therapeutic Area
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product Type
  • 7.3.2 By Specialty / Therapeutic Area
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product Type
  • 7.4.2 By Specialty / Therapeutic Area
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product Type
  • 7.5.2 By Specialty / Therapeutic Area
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product Type
  • 7.6.2 By Specialty / Therapeutic Area
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL HEMOSTATIC AGENTS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Baxter International Inc
  • 9.2.2 Ethicon Inc
  • 9.2.3 Becton
  • 9.2.4 Dickinson And Company (BD)
  • 9.2.5 B. Braun SE
  • 9.2.6 Pfizer Inc
  • 9.2.7 Teleflex Incorporated
  • 9.2.8 CryoLife Inc
  • 9.2.9 Integra LifeSciences Holdings Corporation
  • 9.2.10 Advanced Medical Solutions Group Plc
  • 9.2.11 GELITA AG